EDUCATION > Educational Programs > E-Learning > Videos/Webcasts > 2012 Annual Meeting Webcasts > The Medical Management of BPH > Module 2: Medical Treatment Using Alpha Blockers

Module 2: Medical Treatment Using Alpha Blockers

Learning Objectives

After participating in this activity, participants should be able to:

  • realize the benefit of and need for differentiated medical therapy of men with LUTS and BPH
  • distinguish mechanisms of action of commonly used drugs for LUTS and BPH
  • describe the treatment options for men with minimally symptomatic BPH

Faculty/Authors

Claus G. Roehrborn, MD
Professor and Chair, Department of Urology
UT Southwestern Medical Center at Dallas
Dallas, TX
Disclosures: Roehrborn, Claus: GlaxoSmithKline: Consultant/Advisor

Christopher Chapple, BSc, MD, FRCS (Urol)
Honorary Senior Lecturer of Urology, University of Sheffield
Consultant Urological Surgeon, Royal Hallamshire Hospital
Sheffield, United Kingdom
Disclosures: Chapple, Christopher R.: Pfizer: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Recordati: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Astellas: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Allergan: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; American Medical Systems: Consultant or Advisor,Scientific Study or Trial ; Lilly: Consultant or Advisor

Medical Treatment Using Alpha Blockers – Anything New?

Christopher Chapple, BSc, MD, FRCS (Urol)


5 Alpha Reductase Inhibitors and Combination Therapy

Claus G. Roehrborn, MD

Medical Treatment Using Alpha Blockers – Anything New?


Chapple CR et al. Eur Urol Suppl 2005; 4:33–44

Chapple et al. Eur Urol 59: 342–352, 2011

Djavan et al. Eur Urol 1999; 36:1–13

Marks et al J Urol 181, 2634, 2009

Marks LS . J Urol 181: 2634–2640, 2009 – Chapple C. Eur Urol 59 : 342–352, 2011

Tatemichi S et al., Yakugaku Zasshi 126: 209–216 (2006)

Van Kerrebroeck P et al. Eur Urol 2000; 37:306–313

5 Alpha Reductase Inhibitors and Combination Therapy


Boyle P et al. Eur Urol 2004;45:620–6

McConnell JD, et al. N Engl J Med. 2003;349(25):2387–2398

Mochtar CA et al. Urology. 2005;65:300–305

Roehrborn CG, et al. Eur Urol. 2010;57(1):123–131

Roehrborn CG, et al. Urology. 2011;78(3):641–646

Souverein PC et al. Eur Urol 2003;43:528–34

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT